Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Jynge

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Biochemical Pharmacology|May 12, 2024
Comments on "Clinically relevant therapeutic approaches against acetaminophen (APAP) hepatotoxicity and acute liver failure"Jan Olof G Karlsson, Per Jynge
Journal of Pharmacological Sciences|March 22, 2025
Letter to the editorJan Olof G Karlsson, Per Jynge
International Journal of Molecular Sciences|April 27, 2024
Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca<sub>4</sub>Mn(DPDP)<sub>5</sub>, MnDPDP and DPDPJan Olof G Karlsson, Per Jynge
Acta Oncologica (Stockholm, Sweden)|December 16, 2017
Is it possible to draw firm conclusions from the PLIANT trial?Jan Olof G Karlsson, Per Jynge
Antioxidants (Basel, Switzerland)|December 24, 2021
The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOxJan Olof G Karlsson, Per Jynge, Louis J Ignarro
Antioxidants (Basel, Switzerland)|March 29, 2023
Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn<sup>2+</sup> and Oxaliplatin-Associated Pt<sup>2</sup>Jan Olof G Karlsson, Per Jynge, Louis J Ignarro
Antioxidants (Basel, Switzerland)|October 14, 2020
May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?Jan Olof G Karlsson, Per Jynge, Louis J Ignarro
Translational Oncology|July 3, 2017
Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)Jan Olof G Karlsson, Rolf Gg Andersson, Per Jynge
Magnetic Resonance in Medicine|September 1, 2007
Dynamic water changes in excised rat myocardium assessed by continuous distribution of T1 and T2Morten Bruvold, John Georg Seland, Heidi Brurok, et al.
Cancer Research|January 7, 2006
The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide dismutase mimetic activityJan Olof G Karlsson, Heidi Brurok, Rob Towart, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Biochemical Pharmacology|May 12, 2024
Comments on "Clinically relevant therapeutic approaches against acetaminophen (APAP) hepatotoxicity and acute liver failure"Jan Olof G Karlsson, Per Jynge
Journal of Pharmacological Sciences|March 22, 2025
Letter to the editorJan Olof G Karlsson, Per Jynge
International Journal of Molecular Sciences|April 27, 2024
Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca<sub>4</sub>Mn(DPDP)<sub>5</sub>, MnDPDP and DPDPJan Olof G Karlsson, Per Jynge
Acta Oncologica (Stockholm, Sweden)|December 16, 2017
Is it possible to draw firm conclusions from the PLIANT trial?Jan Olof G Karlsson, Per Jynge
Antioxidants (Basel, Switzerland)|December 24, 2021
The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOxJan Olof G Karlsson, Per Jynge, Louis J Ignarro
Antioxidants (Basel, Switzerland)|March 29, 2023
Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn<sup>2+</sup> and Oxaliplatin-Associated Pt<sup>2</sup>Jan Olof G Karlsson, Per Jynge, Louis J Ignarro
Antioxidants (Basel, Switzerland)|October 14, 2020
May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?Jan Olof G Karlsson, Per Jynge, Louis J Ignarro
Translational Oncology|July 3, 2017
Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)Jan Olof G Karlsson, Rolf Gg Andersson, Per Jynge
Magnetic Resonance in Medicine|September 1, 2007
Dynamic water changes in excised rat myocardium assessed by continuous distribution of T1 and T2Morten Bruvold, John Georg Seland, Heidi Brurok, et al.
Cancer Research|January 7, 2006
The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide dismutase mimetic activityJan Olof G Karlsson, Heidi Brurok, Rob Towart, et al.
Pageof 3